Taking into account all the evidence presented in this study, it suggests that targeting USP20 and/or ULK1 could potentially hold therapeutic promise for individuals affected by HERC2-related disorder and Angelman syndrome. This evidence concerns the gene USP20 and Angelman syndrome.